Premature Ejaculation Study

Premature Ejaculation is one of the most common male sexual health conditions, affecting an estimated 1 in 3 men at some point in their lives. For some, this is a lifelong experience - referred to as Lifelong Premature Ejaculation. Where ejaculation occurs within one minute of vaginal penetration, beginning with a man’s very first sexual encounters.

For many men, premature ejaculation can lead to feelings of frustration, embarrassment, or emotional distress, especially when it impacts their confidence, relationships, or sense of control during intimacy. These challenges are real, and they are more common than many realise. 

While treatments do exist, options like daily medications or SSRIs are not always practical for everyone. They may cause unwanted side effects and often aren’t effective when taken on-demand. That’s why research into new, fast-acting treatment approaches is so important – to offer men more choice, greater control and better support for their sexual and emotional wellbeing. 

This clinical study is evaluating an investigational on-demand oral tablet designed to support men living with Lifelong Premature Ejaculation. The treatment aims to delay ejaculation, improve control and sexual satisfaction, and reduce emotional distress associated with the condition.

Researchers hope it may offer a new option for men seeking relief without the drawbacks of long-term medications. This study is an important step toward expanding treatment choices and improving quality of life for those affected.

Participants in this study will be asked to take a sublingual tablet placed under the tongue – either the investigational medication or a placebo – approximately 15 minutes before vaginal penetration during sexual activity.

Throughout the study, participants will use a secure mobile eDiary to confidentially log key information about their sexual experiences, including the time of medication intake and intercourse.

In addition to at-home tracking, participants will attend regular clinic visits for health assessments, safety monitoring, and to complete questionnaires about their experience and overall well-being.

If eligible, participants will complete two 4-week treatment periods - one receiving the investigational medication and the other a placebo - in a randomized order, with a 4-week break (washout period) in between. Every participant will receive both the study medication and a placebo over the course of the study.

After both phases are complete, researchers will carefully review all collected information to evaluate the potential effects of the treatment.

Why join this clinical research study?

·         Gain early access to a new potential treatment at no cost

·         Contribute to research for men with lifelong premature ejaculation

·         Receive health checks and advice from our professional medical team